Parenteral Anticoagulants

Slides:



Advertisements
Similar presentations
Volume 123, Issue 4, Pages (April 2003)
Advertisements

Volume 32, Issue 1, Pages (July 1957)
Tell-tale Telangiectasias
Colloquium on Therapy of Right Heart Failure
Anesthes. 2013;118(6): doi: /ALN.0b013e318289bcba Figure Legend:
Environmental Causes of Cancer of the Lung Other Than Tobacco Smoke
When to Be Rash About a Fever and Headache
Bovine Tuberculosis Eradication
Improving CPR Performance
Hyperbaric Oxygenation in Cardiac and Pulmonary Disease
Volume 121, Issue 2, Pages (February 2002)
Air Pollution and Chest Disease
Navin K. Jain, MD, Thiam H. Lie, MD, FCCP  CHEST 
Special Treatment Issues in Non-small Cell Lung Cancer
Advance Directive Education During Pulmonary Rehabilitation
Volume 107, Issue 5, Pages (May 1995)
Frank W. Ewald, MD, FCCP, Albert H. Scherff, MD  CHEST 
Screening for Lung Cancer
Prevention of VTE in Orthopedic Surgery Patients
COUNTERPOINT: Is the Apnea-Hypopnea Index the Best Way to Quantify the Severity of Sleep-Disordered Breathing? No  Naresh M. Punjabi, MD, PhD, FCCP  CHEST 
Oral Anticoagulant Therapy
Treatment of Small Cell Lung Cancer
Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis
Oral Anticoagulant Therapy
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Chronic Cough Due to Nonasthmatic Eosinophilic Bronchitis
Diagnostic Surgical Pathology in Lung Cancer
Medical Education in the Clouds
Volume 143, Issue 5, Pages e437S-e454S (May 2013)
Jose Cardenas-Garcia, MD, David Feller-Kopman, MD, FCCP  CHEST 
Counterpoint: Should Lactate Clearance Be Substituted for Central Venous Oxygen Saturation as Goals of Early Severe Sepsis and Septic Shock Therapy? No 
Volume 124, Issue 6, Pages (December 2003)
Volume 142, Issue 1, Pages (July 2012)
Arterial Line or Cuff BP?
New Antithrombotic Drugs
Prevention of VTE in Orthopedic Surgery Patients
Spread the Word About CHEST in 2018
IV Immunoglobulin for Autoimmune Heparin-Induced Thrombocytopenia
Millennial Health Care
Treatment of Tobacco Use in Lung Cancer
Antithrombotic Therapy for VTE Disease
Details and Difficulties Regarding the New Lung Cancer Staging System
Volume 141, Issue 2, Pages e89S-e119S (February 2012)
Primary and Secondary Prevention of Cardiovascular Disease
Some Historical Notes on Behçet's Disease
Point: Should Medicare Allow Respiratory Therapists to Independently Practice and Bill for Educational Activities Related to COPD? Yes  Thomas M. Fuhrman,
Sundeep Salvi, MD, DNB, PhD, FCCP, Peter J. Barnes, DM, FCCP  CHEST 
Volume 104, Issue 1, Pages 1-2 (July 1993)
Reversal of the Anticoagulant Effects of Warfarin by Vitamin K1
Imaging for the Management of Community-Acquired Pneumonia
Spread the Word About CHEST in 2015
The identification and management of heparin-induced thrombocytopenia in the vascular patient  Glenn M. LaMuraglia, MD, Rabih Houbballah, MD, Michael.
Case of Aspergillosis Treated with Amphotericin ‘B’
Brahms' Lullaby Revisited
Volume 138, Issue 4, Pages (October 2010)
Evolution in Reimbursement for Sleep Studies and Sleep Centers
Bedside Calibration Of Pulmonary Artery Catheters
Invasive Pulmonary Aspergillosis
Pulmonary Manifestations in a Case of Multiple Myeloma
Engagement and Education
Do CIs Give You Confidence?
Effects of Beta-Adrenergic Agents on Hypokalemia
A Single Nasal Prong for Continuous Oxygen Therapy
Nasal Airflow in Sleep-Disordered Breathing
Volume 42, Issue 2, Pages (August 1962)
Counterpoint: Should Medicare Allow Respiratory Therapists to Independently Practice and Bill for Educational Activities Related to COPD? No  Katherine.
Volume 133, Issue 4, Pages (April 2008)
Volume 141, Issue 2, Pages e89S-e119S (February 2012)
Arterial Line or Cuff BP?
New Members of the Editorial Board
Presentation transcript:

Parenteral Anticoagulants David A. Garcia, MD, Trevor P. Baglin, MBChB, PhD, Jeffrey I. Weitz, MD, FCCP, Meyer Michel Samama, MD  CHEST  Volume 141, Issue 2, Pages e24S-e43S (February 2012) DOI: 10.1378/chest.11-2291 Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 1 Inactivation of clotting enzymes by heparin. Top, ATIII is a slow inhibitor without heparin. Middle, Heparin binds to ATIII through a high-affinity pentasaccharide and induces a conformational change in ATIII, thereby converting ATIII from a slow inhibitor to a very rapid inhibitor. Bottom, ATIII binds covalently to the clotting enzyme, and the heparin dissociates from the complex and can be reused. AT = antithrombin. (Reprinted with permission from Hirsh et al.7) CHEST 2012 141, e24S-e43SDOI: (10.1378/chest.11-2291) Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 2 Molecular weight distribution of LMWHs and heparin. LMWH = low-molecular-weight heparin. (Reprinted with permission from CHEST.7) CHEST 2012 141, e24S-e43SDOI: (10.1378/chest.11-2291) Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 3 Low doses of heparin clear rapidly from plasma through a saturable (cellular) mechanism and the slower, nonsaturable, dose-independent mechanism of renal clearance. Very high doses of heparin are cleared predominantly through the slower nonsaturable mechanism of clearance. t1/2 = half-life. (Reprinted with permission from CHEST.7) CHEST 2012 141, e24S-e43SDOI: (10.1378/chest.11-2291) Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 4 As heparin enters the circulation, it binds to heparin-binding proteins (ie, other plasma proteins), endothelial cells, macrophages, and ATIII. Only heparin with the high-affinity pentasaccharide binds to ATIII, but binding to other proteins and to cells is nonspecific and occurs independently of the ATIII binding site. See Figure 1 legend for expansion of abbreviation. (Reprinted with permission from CHEST.7) CHEST 2012 141, e24S-e43SDOI: (10.1378/chest.11-2291) Copyright © 2012 The American College of Chest Physicians Terms and Conditions